Industry Overview - The medical device industry in China is expected to maintain steady growth, with an overall growth rate of around 10% [2] - Policy support for equipment replacement is expected to drive growth, particularly in surgical and consumable segments due to accelerated aging [2] - The medical device sector is at the bottom of the current policy cycle, with expectations of improvement due to policy-driven equipment replacement [2] - The impact of centralized procurement on consumables has weakened, and expectations have stabilized [2] Global Perspective - The global medical device market is dominated by US and European companies, with 29 companies having a market cap exceeding $20 billion as of October 11, 2024 [5] - Chinese companies are rapidly catching up, with significant progress in high-end imaging, chemical luminescence, and gene sequencing, with overseas revenue share expected to increase by 15 percentage points [2] - The top 10 medical device companies by market cap are primarily in vascular, orthopedic, and IVD sectors, with revenues mostly exceeding $10 billion [5] Domestic Market Dynamics - Low-end medical devices in China have achieved a high level of domestic production, with a focus on high-end alternatives such as chemical luminescence, electrophysiology, endoscopy, CT/MRI, gene sequencing, and high-end ultrasound [10] - The domestic market for medical devices is expected to benefit from policy-driven equipment replacement, with an estimated industry benefit of 20-30 billion yuan [38] - The 2022 Q4 policy stimulus led to a surge in procurement, with the medical device market growing by 101.44% year-on-year [18] Key Companies and Performance - Key companies in the medical device sector include Mindray Medical, United Imaging Healthcare, and Aohua Endoscopy, with Mindray Medical showing a 14% year-on-year revenue growth in 2023 [30] - Mindray Medical's overseas revenue accounted for 39% of total revenue in 2023, with significant growth in the Asia-Pacific, North America, Latin America, and Europe regions [66] - United Imaging Healthcare's overseas revenue grew by 56% in 2023, with a 15% share of total revenue [66] International Expansion - Chinese medical device companies are expanding internationally, with a focus on high-value consumables and high-end equipment [52] - Companies like Mindray Medical, United Imaging Healthcare, and HuiTai Medical have seen rapid growth in overseas revenue over the past three years [52] - The core competitive advantage of Chinese medical devices in non-US public markets lies in their high cost-performance ratio, with companies leveraging domestic engineering resources and cost advantages to provide comprehensive services [57] Policy and Market Trends - The Chinese government has introduced policies to support large-scale equipment updates and consumer goods replacement, with a target of increasing investment in medical and other fields by 25% by 2027 [37] - The policy-driven equipment replacement is expected to bring significant incremental growth to the medical device industry, with an estimated terminal market size of 1500-1600 billion yuan in 2024 [38] - The 2022 Q4 policy stimulus led to a surge in procurement, with the medical device market growing by 101.44% year-on-year [18] Future Outlook - The medical device industry in China is expected to maintain steady growth, with a focus on high-end alternatives and international expansion [2][10] - Policy-driven equipment replacement and the aging population are expected to drive growth in the surgical and consumable segments [2] - Chinese companies are expected to continue their rapid catch-up in high-end imaging, chemical luminescence, and gene sequencing, with overseas revenue share expected to increase by 15 percentage points [2]

Industry Investment Rating - The report does not explicitly provide an overall investment rating for the industry, but it highlights significant potential for growth in the pharmaceutical sector, particularly in innovation-driven areas such as oncology, immunology, and diabetes [6][8][28] Core Views - The pharmaceutical industry is undergoing a transformation driven by innovation, policy changes, and global competition. Key areas of focus include oncology, immunology, and diabetes, with significant opportunities in ADC (Antibody-Drug Conjugate) and TCE (T-Cell Engager) technologies [6][8][28] - The report emphasizes the importance of global competitiveness, particularly for Chinese pharmaceutical companies, which are increasingly participating in international markets through licensing deals and innovative drug development [8][13][19] - The industry is expected to benefit from policy support, increased R&D investment, and a shift towards high-value innovative drugs, with a focus on both domestic and international markets [6][13][28] Key Areas of Opportunity Oncology - Oncology remains a critical area of focus, with significant advancements in IO (Immuno-Oncology) and ADC technologies. Key companies to watch include Kangfang Biotech, Kelun-Biotech, and Baili Pharmaceuticals, which are at the forefront of global competition in these areas [31][33][36] - The report highlights the potential for Chinese companies to lead in the development of next-generation cancer therapies, particularly in ADC and IO combination therapies [31][33][36] Immunology - Immunology is another key area, with a focus on TCE and CAR-T therapies for autoimmune diseases. Companies like Innovent Biologics, JW Therapeutics, and Legend Biotech are making significant strides in this field [43][48] - The report notes the potential for Chinese companies to capitalize on global trends in immunology, particularly through licensing deals and international collaborations [43][48] Diabetes and Obesity - The global market for GLP-1 drugs is expanding rapidly, with significant opportunities for Chinese companies to enter the market. Key players include Hengrui Medicine, Innovent Biologics, and Silver Medical, which are developing next-generation GLP-1 therapies [39][41] - The report predicts that 2025 will be a pivotal year for the commercialization of GLP-1 drugs in China, with increased competition and market expansion [39][41] Medical Devices - The medical device sector is expected to see growth driven by domestic demand and international expansion. Companies like Mindray, United Imaging, and Aohua Medical are well-positioned to benefit from policy support and increased demand for high-end medical equipment [78][79] - The report highlights the potential for Chinese medical device companies to increase their global market share, particularly in areas like IVD (In Vitro Diagnostics) and high-end imaging [78][79] Global Trends and Competitive Landscape - The report underscores the importance of global competitiveness, with Chinese companies increasingly participating in international markets through licensing deals, innovative drug development, and strategic collaborations [8][13][19] - The global pharmaceutical market is highly competitive, with significant opportunities for Chinese companies to leverage their R&D capabilities and cost advantages to gain a foothold in key therapeutic areas [8][13][19] Policy and Market Dynamics - The report highlights the role of policy support in driving innovation and growth in the pharmaceutical industry. Recent policy changes in China, including DRG exemptions and increased support for innovative drugs, are expected to benefit the industry [52][59] - The report also notes the impact of anti-corruption measures on the industry, which have accelerated the shift towards high-value innovative drugs and reduced the market share of less effective treatments [52][59] Conclusion - The pharmaceutical industry is poised for significant growth, driven by innovation, policy support, and global competition. Key areas of opportunity include oncology, immunology, diabetes, and medical devices, with Chinese companies well-positioned to capitalize on these trends [6][8][28][78]

Investment Rating - The industry investment rating is "Outperform the Market" [2] Core Viewpoints - The report emphasizes the recovery of consumer expectations and the initiation of a new round of optimization and transformation, highlighting the importance of marginal changes in the market [17] - The beauty and personal care sector, along with leading cross-border e-commerce companies, is expected to continue stable growth, while supermarkets and jewelry sectors may face pressure due to terminal demand [17] Summary by Relevant Sections Platform Performance - Douyin achieved a significant sales increase of 69.01% year-on-year during the Double 11 shopping festival, with skincare and makeup categories growing by 76.81% and 61.44% respectively [4] - Taobao's platform contributed over 50% to GMV, with a growth rate of 25.8% in the beauty sector [4] Category Insights - Skincare sets saw a remarkable growth rate of 91.74% in October, driven by high demand for anti-aging products [5] - Medical dressing sales surged by 593.08% year-on-year during Double 11, with top brands contributing over 75% of the market share [5] Brand Performance - Foreign brands dominated the sales landscape, with a ratio of 8:2 in the top 10 brands on platforms, while domestic brands are also gaining traction [6] - Notable growth was observed in brands like L'Oréal and Estée Lauder, with several foreign brands experiencing over 50% growth [6] Key Company Reports - Perleya maintained its top position in beauty sales across multiple platforms, with a year-on-year growth exceeding 10% on Tmall and 60% on Douyin [12] - Betainy’s brand Winona entered the Tmall beauty industry top 10 for the eighth consecutive year, showcasing strong performance in both online and offline channels [13] - Upbeauty’s brands, including Han Shu and NEWPAGE, reported significant growth rates of 44% and 238% respectively [14] - Juzibio's product, Kefu Mei, saw an 80% increase in GMV across all channels, with strong performances on Tmall and Douyin [16]

Investment Rating - The investment rating for the industry is "Outperform the Market" and is maintained [2]. Core Viewpoints - The industry is currently facing significant losses, particularly in the copper foil sector, where product prices are substantially below the average industry cost. The copper foil industry association has issued multiple statements advocating for price adjustments to stabilize the market [4][5]. - The association's recent communications emphasize the need for companies to focus on innovation and management improvements rather than engaging in destructive price competition, which has led to negative cash flow for many firms [5]. - The report suggests that the worst period for the copper foil industry may be over, with expectations for price increases in the near future. Companies to watch include Defu Technology, Nord Shares, Jiayuan Technology, Zhongyi Technology, and Tongguan Copper Foil [5]. Summary by Sections Industry Overview - The copper foil industry is experiencing severe internal competition, leading to prices that are unsustainably low compared to production costs. The cost range for 6μm lithium battery copper foil is between 20,000 to 22,000 yuan per ton, while for 35μm HTE electronic circuit copper foil, it is between 16,000 to 18,000 yuan per ton [5]. Market Dynamics - Many companies in the industry are selling products below variable costs, resulting in negative operational cash flows, which threatens their survival and the industry's sustainability [5]. - The association has called for companies to adjust processing fees above cost levels to escape the current loss situation and to maintain a healthy market environment [5]. Future Outlook - The report indicates a potential shift towards price recovery in the copper foil industry, driven by the association's initiatives and the recognition of the need for sustainable practices [5].

证券研究报告 （优于大市，维持） | --- | --- | |----------------------------------------------------------------------------------|------------------------------------------------| | | | | | | | 10 | 月重卡销量环比增长， | | 新能源重卡表现亮眼 刘一鸣（汽车行业首席分析师） SAC 号码： S0850522120003 SAC | 张觉尹（汽车行业分析师） 号码： S0850523020001 | | 潘若婵（联系人） | 张予名（联系人） | 2024年11月19日 | --- | --- | --- | --- | --- | --- | --- | |----------|------------------------------------------------------------------|-------------------------------|-----------------------|---------- ...

[Table_MainInfo]行业研究/交通运输 证券研究报告 行业周报 2024 年 11 月 19 日 [Table_InvestInfo] 投资评级 优于大市 维持 [Table_AuthorInfo] 市场表现 [Table_QuoteInfo] -8.68% -3.44% 1.80% 7.05% 12.29% 17.54% 2023/11 2024/2 2024/5 2024/8 交通运输 海通综指 资料来源：海通证券研究所 相关研究 [Table_ReportInfo] 《周报：我国内河港口首次运用"船边放 行、智能分流"作业模式》2024.11.14 《周报：中国加拿大直航增班即将启动》 2024.11.05 《从航空十倍股，我们看到什么？》 2024.11.14 分析师:虞楠 Tel:(021)23219382 Email:yun@haitong.com 证书:S0850512070003 分析师:罗月江 Tel:(010)58067993 Email:lyj12399@haitong.com 证书:S0850518100001 联系人:吕春雨 Tel:(021)23185678 Email ...

[Table_MainInfo]行业研究/公用事业 证券研究报告 [Table_AuthorInfo] [Table_InvestInfo] 投资评级 优于大市 维持 市场表现 [Table_QuoteInfo] -15.30% -10.37% -5.44% -0.51% 4.42% 9.35% 2023/4 2023/7 2023/10 2024/1 公用事业 海通综指 资料来源：海通证券研究所 相关研究 [Table_ReportInfo] 《能源法颁布，财政万亿开启》2024.11.11 《能源法颁布，财政万亿开启》2024.11.11 《火电：Q3 业绩增速低点，Q4 或明显好 转》2024.11.04 分析师:吴杰 Tel:(021)23183818 Email:wj10521@haitong.com 证书:S0850515120001 分析师:傅逸帆 Tel:(021)23185698 Email:fyf11758@haitong.com 证书:S0850519100001 联系人:阎石 Tel:(021)23185741 Email:ys14098@haitong.com 联系人:胡鸿程 Tel ...

Investment Rating - The report maintains an "Outperform" rating for the industry [1] Core Insights - The rapid growth of renewable energy installations is creating contradictions within the electricity reform landscape, with significant increases in photovoltaic (PV) and wind power capacity leading to greater consumption pressure [2][4] - As of 2023, the newly installed PV capacity reached approximately 216 GW, while wind power added about 76 GW, indicating a fast expansion of renewable energy sources [2] - The report forecasts that by 2025, the ratio of thermal power to renewable energy will decline further, with wind and solar installations expected to surpass thermal power capacity [2] Summary by Sections Section 1.1: Contradictions in Electricity Reform - The report highlights the explosive growth of renewable energy installations, with a notable increase in PV and wind power, leading to challenges in energy consumption management [2] Section 1.2: Continued Growth of Photovoltaics - The cost of PV systems is decreasing, with the latest component price at 0.68 CNY/W, and projected to drop to 3 CNY/W by 2025 [4] Section 1.3: Wind Power Resource Scarcity - Wind power projects are facing challenges due to the scarcity of high-quality resources, despite attractive returns on investment [10] Section 1.4: Development Challenges for Energy Storage - The report discusses the difficulties in developing large-scale energy storage solutions while highlighting the potential for commercial storage to flourish [12] Section 1.5: National Unified Electricity Market - The report outlines the potential for a unified electricity market across different regions, which may enhance efficiency and resource allocation [14][15] Section 1.6: Thermal Power Dynamics - Thermal power generation is expected to increase during peak pricing periods, with significant price fluctuations observed in the market [17][24] Section 2.1: Electricity Demand Forecast - The report predicts a tight electricity supply-demand balance, with a projected 6.1% increase in electricity consumption for 2024 [53] Section 2.2: Renewable Energy Installation Growth - The growth rate of renewable energy installations is significantly outpacing that of adjustable power sources, indicating a shift in the energy landscape [54] Section 2.3: Hydropower Utilization - The report provides insights into hydropower utilization hours and the current status of hydropower generation, emphasizing its role in the energy mix [73][77]

Industry Investment Rating - The report suggests a strong recommendation for large-cap stocks, particularly those with low valuations and potential for mergers and acquisitions [87] Core Views - The real estate market is expected to enter a bottoming phase by 2025, with potential for stabilization and recovery as policy effects materialize [3][64] - The industry is shifting from credit protection to value protection, emphasizing asset activation and long-term profitability [72][73][74] - A bull market is anticipated to eliminate low valuations, with a focus on the transition from negative to positive feedback loops [82][83] Dollar Tide Mechanism - The dollar tide mechanism highlights the relationship between US monetary policy and global capital flows, particularly impacting emerging markets and asset prices [5][7] - China's real estate policy cycles have historically aligned with US interest rate changes, with 2020 being the first instance of simultaneous domestic real estate regulation and US rate hikes [11][12] - The current dollar devaluation cycle is expected to benefit Chinese assets, including the real estate market, due to global supply chain demand and the RMB settlement system [8][9] Domestic Real Estate Policy Cycle - The 2023 Politburo meeting marked a shift towards more supportive policies for real estate, with a focus on stabilizing the market and reducing inventory [16][17] - Compared to the 2014 cycle, the current market faces challenges due to varying population cycles and debt levels across cities, making synchronized recovery difficult [28][29] - However, the current market benefits from significant capacity reduction, with new construction and real estate investment at historically low levels, leading to a potential decline in future supply [32][33][34][36] - Land supply has also contracted significantly, with a 22.56% year-on-year decline in land transaction area and a 34.66% decline in transaction value in 2024 [37][39] - Housing prices have adjusted, with first-tier cities seeing a 12.92% decline from their peak and key second-tier cities experiencing a 20.47% decline [41][42][43][44] - Sales volume has also seen a significant adjustment, with a projected 48.38% decline in sales area and a 50.45% decline in sales value from 2021 levels [46][47][48][49] Future Housing Demand - Future housing demand is expected to be driven by urbanization, household registration, and improvement needs, with a projected decline in total demand from 19.70 billion square meters in 2024 to 8.49 billion square meters by 2043 [51][52][53][55] Real Estate Market Bottoming - Inventory pressure has increased, with a 34.52-month inventory clearance cycle in 23 representative cities as of October 2024, indicating a potential bottoming phase [56][57][58] - Sales in 44 key cities have shown a bottoming trend, with a projected narrowing of year-on-year sales growth by 2025 [59][60][61][62] - Developers are expected to go through a cycle of reducing inventory before replenishing it, with investment growth likely to follow sales growth by 1-2 quarters [67][68][69][70] Corporate Strategy Shift - The real estate industry's contribution to GDP has declined, with a shift towards a new growth model focusing on value protection and long-term profitability [72][73][74] - The industry will focus on asset activation, with companies adopting strategies for large-scale mergers, stable growth, and optimized business structures [79][80][81] Investment Recommendations - The report recommends focusing on large-cap stocks with low valuations and potential for mergers and acquisitions, including companies like China Overseas Land & Investment, China Resources Land, and Longfor Group [87]

[Table_MainInfo]行业研究/信息设备/电子元器件 证券研究报告 行业信息点评 2024 年 11 月 19 日 [Table_AuthorInfo] [Table_InvestInfo] 投资评级 优于大市 维持 市场表现 [Table_QuoteInfo] 资料来源：海通证券研究所 | --- | --- | |------------------------------------------------|-----------------------| | | | | 相关研究 | | | [Table_ReportInfo] 《电子行业周报 2024.11.18 | 241111-1115 》 | | 《显示行业观察： | LED 周跟踪 | | （ 11/04-11/10 ）》 | 2024.11.12 | | 《电子行业周报（ | 2024/11/04-11/08 ）》 | 分析师:张晓飞 Email:zxf15282@haitong.com 证书:S0850523030002 联系人:吴小沛 Email:wxp16129@haitong.com 味之素调高 FY2024 电子材料营 ...